VEDVDox by ImmunityBio for Recurrent Glioblastoma Multiforme (GBM): Likelihood of Approval

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

VEDVDox overview

VEDVDox is under development for the treatment of recurrent glioblastoma multiforme. It comprises of doxorubicin with minicells. The drug candidate is administered through intravenous route through infusion. It is developed using EDV (EnGeneIC Delivery Vehicles) mediated drug delivery technology.

It was also under development for the treatment of multiple indications in doxorubicin naive patients.

ImmunityBio overview

ImmunityBio, formerly NantKwest, a clinical-stage biotechnology company is developing therapies and vaccines that complement, harness and amplify the immune system to defeat cancers and infectious diseases. The company product pipeline includes n-803 + bcg for bladder cancer, anktiva + pd-l1 t-hank for lung cancer, anktiva + aldox +pd-l1 t-hank for pancreatic cancer, her2 t-hank for glioblastoma and anktiva + m-cenk for advanced solid tumor. ImmunityBio Anktiva, a lead candidate Anktiva are a novel class of biopharmaceuticals that enhance the therapeutic potential of cytokines, and promote lymphocyte infiltration at a site of disease, improving immune response. The company has operation in Korea, Italy and the US. ImmunityBio is headquartered in San Diego, California, the US.

For a complete picture of VEDVDox’s drug-specific PTSR and LoA scores, buy the report here.